William G Rule1, Nathan R Foster2, Jeffrey P Meyers2, Jonathan B Ashman3, Sujay A Vora3, Timothy F Kozelsky4, Yolanda I Garces4, James J Urbanic5, Joseph K Salama6, Steven E Schild3. 1. Department of Radiation Oncology, Mayo Clinic Arizona, USA. Electronic address: rule.william@mayo.edu. 2. Section of Biomedical Statistics and Informatics, Mayo Clinic Rochester, USA. 3. Department of Radiation Oncology, Mayo Clinic Arizona, USA. 4. Department of Radiation Oncology, Mayo Clinic Rochester, USA. 5. Department of Radiation Oncology, Wake Forest School of Medicine, USA. 6. Department of Radiation Oncology, Duke University School of Medicine, USA.
Abstract
OBJECTIVES: To examine the efficacy of prophylactic cranial irradiation (PCI) in elderly patients with small cell lung cancer (SCLC) (≥70 years of age) from a pooled analysis of four prospective trials. MATERIALS & METHODS:One hundred fifty-five patients with SCLC (limited stage, LSCLC, and extensive stage, ESCLC) participated in four phase II or III trials. Ninety-one patients received PCI (30 Gy/15 or 25 Gy/10) and 64 patients did not receive PCI. Survival was compared in a landmark analysis that included only patients who had stable disease or better in response to primary therapy. RESULTS: Patients who received PCI had better survival than patients who did not receive PCI (median survival 12.0 months vs. 7.6 months, 3-year overall survival 13.2% vs. 3.1%, HR = 0.53 [95% CI 0.36-0.78], p = 0.001). On multivariate analysis of the entire cohort, the only factor that remained significant for survival was stage (ESCLC vs. LSCLC, p = 0.0072). In contrast, the multivariate analysis of patients who had ESCLC revealed that PCI was the sole factor associated with a survival advantage (HR = 0.47 [95% CI 0.24-0.93], p = 0.03). Grade 3 or higher adverse events (AEs) were significantly greater in patients who received PCI (71.4% vs. 47.5%, p = 0.0031), with non-neuro and non-heme being the specific AE categories most strongly correlated with PCI delivery. CONCLUSIONS:PCI was associated with a significant improvement in survival for our entire elderly SCLC patient cohort on univariate analysis. Multivariate analysis suggested that the survival advantage remained significant in patients with ESCLC. PCI was also associated with a modest increase in grade 3 or higher AEs.
RCT Entities:
OBJECTIVES: To examine the efficacy of prophylactic cranial irradiation (PCI) in elderly patients with small cell lung cancer (SCLC) (≥70 years of age) from a pooled analysis of four prospective trials. MATERIALS & METHODS: One hundred fifty-five patients with SCLC (limited stage, LSCLC, and extensive stage, ESCLC) participated in four phase II or III trials. Ninety-one patients received PCI (30 Gy/15 or 25 Gy/10) and 64 patients did not receive PCI. Survival was compared in a landmark analysis that included only patients who had stable disease or better in response to primary therapy. RESULTS:Patients who received PCI had better survival than patients who did not receive PCI (median survival 12.0 months vs. 7.6 months, 3-year overall survival 13.2% vs. 3.1%, HR = 0.53 [95% CI 0.36-0.78], p = 0.001). On multivariate analysis of the entire cohort, the only factor that remained significant for survival was stage (ESCLC vs. LSCLC, p = 0.0072). In contrast, the multivariate analysis of patients who had ESCLC revealed that PCI was the sole factor associated with a survival advantage (HR = 0.47 [95% CI 0.24-0.93], p = 0.03). Grade 3 or higher adverse events (AEs) were significantly greater in patients who received PCI (71.4% vs. 47.5%, p = 0.0031), with non-neuro and non-heme being the specific AE categories most strongly correlated with PCI delivery. CONCLUSIONS: PCI was associated with a significant improvement in survival for our entire elderly SCLCpatient cohort on univariate analysis. Multivariate analysis suggested that the survival advantage remained significant in patients with ESCLC. PCI was also associated with a modest increase in grade 3 or higher AEs.
Authors: A Aupérin; R Arriagada; J P Pignon; C Le Péchoux; A Gregor; R J Stephens; P E Kristjansen; B E Johnson; H Ueoka; H Wagner; J Aisner Journal: N Engl J Med Date: 1999-08-12 Impact factor: 91.245
Authors: Bree R Eaton; Sungjin Kim; David M Marcus; Roshan Prabhu; Zhengjia Chen; Suresh S Ramalingam; Walter J Curran; Kristin A Higgins Journal: Cancer Date: 2013-08-06 Impact factor: 6.860
Authors: R Catane; J G Schwade; I Yarr; A S Lichter; J E Tepper; N R Dunnick; L Brody; H D Brereton; M Cohen; E Glatstein Journal: Int J Radiat Oncol Biol Phys Date: 1981-01 Impact factor: 7.038
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: R Arriagada; T Le Chevalier; A Rivière; P Chomy; I Monnet; E Bardet; J A Santos-Miranda; C Le Péhoux; M Tarayre; S Benhamou; A Laplanche Journal: Ann Oncol Date: 2002-05 Impact factor: 32.976
Authors: N Rodriguez de Dios; P Calvo; M Rico; M Martín; F Couñago; A Sotoca; B Taboada; A Rodríguez Journal: Clin Transl Oncol Date: 2017-04-26 Impact factor: 3.405
Authors: Mathijs L Tomassen; Mieke J Aarts; Max Peters; Anne van Lindert; Dirk K M De Ruysscher; Joost J C Verhoeff; Peter S N van Rossum Journal: Clin Transl Radiat Oncol Date: 2021-02-12
Authors: Cristina Pangua; Jacobo Rogado; Gloria Serrano-Montero; José Belda-Sanchís; Beatriz Álvarez Rodríguez; Laura Torrado; Nuria Rodríguez De Dios; Xabier Mielgo-Rubio; Juan Carlos Trujillo; Felipe Couñago Journal: World J Clin Oncol Date: 2022-06-24